David S Alberts, MD

-
Professor (Retired), Medicine
Biography
Dr. Alberts received his MD in 1966 from the University of Virginia. He conducted his internship at the University of Wisconsin, before becoming a Clinical Associate in medical oncology at the National Cancer Institute’s Baltimore Cancer Research Center. Dr. Alberts conducted his internal medicine residency at the University of Minnesota and then served on the faculty of the University of California, San Francisco, for five years. He joined The University of Arizona College of Medicine in 1975 as an Assistant Professor, where he has served for more than 40 years. He became the UA Cancer Center’s director in 2005 and retired from the position in June 2013.
Cancer Focus
Throughout his career, David Alberts, MD, has focused on translational cancer prevention and treatment research. The emphasis of his laboratory and clinical research has been on the chemoprevention and treatment of cancers of the breast, colon, ovary, and skin. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at The University of Arizona Cancer Center for molecularly-targeted chemopreventive agents. His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches.
Selected Publications
Martinez, J. A., J. Yang, B. C. Wertheim, D. J. Roe, A. Schriewer, P. Lance, D. S. Alberts, B. D. Hammock, and P. A. Thompson, "Celecoxib use and circulating oxylipins in a colon polyp prevention trial.", PLoS One, vol. 13, issue 4, pp. e0196398, 2018. PMCID: PMC5919576 PMID: 29698447
Thomson, C. A., T. E. Crane, A. Miller, D. O. Garcia, K. Basen-Engquist, and D. S. Alberts, "A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) Study.", Contemp Clin Trials, vol. 49, pp. 181-9, 2016 07. PMCID: PMC5108358 PMID: 27394382
Glazer, E. S., H. Helen Zhang, K. A. Hill, C. Patel, S. T. Kha, M. L. Yozwiak, H. Bartels, N. N. Nafissi, J. C. Watkins, D. S. Alberts, et al., "Evaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology.", Cancer Med, vol. 5, issue 10, pp. 2841-2847, 2016 10. PMCID: PMC5083737 PMID: 27666740
Glazer, E. S., P. H. Bartels, J. Liang, A. R. Prasad, M. L. Yozwiak, M. Krutzsch, C. Clark, S. Kha, H. G. Bartels, J. G. Einspahr, et al., "High Proportion of Nuclear Phenotype Identifies Aggressive Cutaneous Squamous Cell Carcinoma.", Anal Quant Cytopathol Histpathol, vol. 37, issue 5, pp. 302-9, 2015 Oct. PMID: 26856115
Crane, T. E., B. R. Khulpateea, D. S. Alberts, K. Basen-Engquist, and C. A. Thomson, "Dietary intake and ovarian cancer risk: a systematic review.", Cancer Epidemiol Biomarkers Prev, vol. 23, issue 2, pp. 255-73, 2014 Feb. PMCID: PMC4077283 PMID: 24142805
Garcia, F. A. R., T. Cornelison, T. Nuño, D. L. Greenspan, J. W. Byron, C-H. Hsu, D. S. Alberts, and H-H. Sherry Chow, "Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.", Gynecol Oncol, vol. 132, issue 2, pp. 377-82, 2014 Feb. PMCID: PMC3955221 PMID: 24388920
Chase, D. M., S. J. Gibson, D. A. Sumner, J. W. Bea, and D. S. Alberts, "Appropriate use of complementary and alternative medicine approaches in gynecologic cancers.", Curr Treat Options Oncol, vol. 15, issue 1, pp. 14-26, 2014 Mar. PMID: 24398574